Physician profile
Sonali P Majmudar
NPI 1528164118
$136,319.92
in general payments reported to CMS, 2019-2025
36 companies · $59K in 2025
The $59K reported for 2025 was more than what 96% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $130 · 2021: $66.98 · 2022: $2,706 · 2023: $35K · 2024: $39K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $83K · Consulting Fee: $29K · Travel and Lodging: $11K · Food and Beverage: $10K · Education: $84.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $82,719.50 |
| Consulting Fee | $29,252.72 |
| Travel and Lodging | $10,929.52 |
| Food and Beverage | $10,132.34 |
| Education | $84.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $64,559.77 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Incyte Corporation | $29,574.33 | 2023-2025 | Opzelura, Opzelura |
| Lilly USA, LLC | $13,506.95 | 2025 | Ebglyss |
| Novartis Pharmaceuticals Corporation | $5,523.29 | 2020-2025 | |
| Genzyme Corporation | $5,143.93 | 2019-2025 | |
| Csl Behring | $3,742.46 | 2025 | Andembry |
| Genentech, INC. | $3,337.49 | 2023 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $3,275.30 | 2023-2025 | Takhzyro, Cuvitru |
| Astrazeneca Pharmaceuticals Lp | $2,396.18 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Genentech USA, INC. | $1,712.58 | 2022-2025 | Xolair |
| Blueprint Medicines Corporation | $872.89 | 2023-2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $641.66 | 2020-2025 | Dupixent |
| Aquestive Therapeutics, INC. | $283.98 | 2024-2025 | |
| Pfizer INC. | $237.72 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $231.92 | 2019-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $203.79 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $145.32 | 2022 | |
| Biocryst US Sales Co., LLC | $132.30 | 2022-2024 | Orladeyo |
| Amgen INC. | $97.92 | 2022-2025 | Tezspire |
| Abbvie INC. | $90.23 | 2023 | |
| Biotissue Holdings INC. | $77.15 | 2023 | |
| Pharming Healthcare, INC. | $75.98 | 2024-2025 | Ruconest |
| Cycle Pharmaceuticals INC | $72.64 | 2025 | Sajazir |
| Sun Pharmaceutical Industries INC. | $53.46 | 2025 | |
| Hospira, INC. | $51.63 | 2025 | |
| Covis Pharma Gmbh | $44.76 | 2022 | |
| Merck Sharp & Dohme LLC | $42.62 | 2021-2023 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $40.23 | 2023 | Zeposia |
| Kyowa Kirin, INC. | $36.94 | 2025 | |
| Hikma Pharmaceuticals USA | $22.70 | 2024 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $17.37 | 2025 | Neffy |
| Alk-Abello, INC | $16.91 | 2019 | |
| Phadia US INC. | $15.74 | 2023 | Immunocap |
| Biogen, INC. | $15.33 | 2022 | |
| Ionis Pharmaceuticals, INC. | $14.75 | 2025 | Dawnzera |
| Kaleo, INC. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonali Majmudar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.